These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 23319096)

  • 1. Antiplatelet therapy: Does prasugrel or ticagrelor suffice in patients with STEMI?
    Agrawal K; Bhatt DL
    Nat Rev Cardiol; 2013 Mar; 10(3):121-2. PubMed ID: 23319096
    [No Abstract]   [Full Text] [Related]  

  • 2. Pretreatment platelet reactivity contribution to residual, post-treatment platelet reactivity in prasugrel-treated and ticagrelor-treated patients.
    Alexopoulos D; Xanthopoulou I; Davlouros P; Tsigkas G; Damelou A; Theodoropoulos KC; Gkizas V; Hahalis G
    J Thromb Haemost; 2013 Feb; 11(2):381-4. PubMed ID: 23216658
    [No Abstract]   [Full Text] [Related]  

  • 3. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction.
    Alexopoulos D; Xanthopoulou I; Gkizas V; Kassimis G; Theodoropoulos KC; Makris G; Koutsogiannis N; Damelou A; Tsigkas G; Davlouros P; Hahalis G
    Circ Cardiovasc Interv; 2012 Dec; 5(6):797-804. PubMed ID: 23169985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of double (360 mg) ticagrelor loading dose with standard (60 mg) prasugrel loading dose in ST-elevation myocardial infarction patients: the Rapid Activity of Platelet Inhibitor Drugs (RAPID) primary PCI 2 study.
    Parodi G; Bellandi B; Valenti R; Migliorini A; Marcucci R; Carrabba N; Giurlani L; Gensini GF; Abbate R; Antoniucci D
    Am Heart J; 2014 Jun; 167(6):909-14. PubMed ID: 24890542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome.
    Kazi DS; Garber AM; Shah RU; Dudley RA; Mell MW; Rhee C; Moshkevich S; Boothroyd DB; Owens DK; Hlatky MA
    Ann Intern Med; 2014 Feb; 160(4):221-32. PubMed ID: 24727840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry.
    Christ G; Siller-Matula JM; Francesconi M; Dechant C; Grohs K; Podczeck-Schweighofer A
    BMJ Open; 2014 Oct; 4(10):e005781. PubMed ID: 25361837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study.
    Alexopoulos D; Galati A; Xanthopoulou I; Mavronasiou E; Kassimis G; Theodoropoulos KC; Makris G; Damelou A; Tsigkas G; Hahalis G; Davlouros P
    J Am Coll Cardiol; 2012 Jul; 60(3):193-9. PubMed ID: 22789884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
    Aradi D; Komócsi A; Vorobcsuk A; Serebruany VL
    Thromb Haemost; 2013 Jan; 109(1):93-101. PubMed ID: 23197191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized comparison of ticagrelor versus prasugrel in patients with acute coronary syndrome and planned invasive strategy--design and rationale of the iNtracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 5 trial.
    Schulz S; Angiolillo DJ; Antoniucci D; Bernlochner I; Hamm C; Jaitner J; Laugwitz KL; Mayer K; von Merzljak B; Morath T; Neumann FJ; Richardt G; Ruf J; Schömig G; Schühlen H; Schunkert H; Kastrati A;
    J Cardiovasc Transl Res; 2014 Feb; 7(1):91-100. PubMed ID: 24371012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response to letter regarding article, "Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction".
    Alexopoulos D; Xanthopoulou I; Gkizas V; Kassimis G; Theodoropoulos K; Makris G; Koutsogiannis N; Damelou A; Tsigkas G; Davlouros P; Hahalis G
    Circ Cardiovasc Interv; 2013 Apr; 6(2):e29. PubMed ID: 23591428
    [No Abstract]   [Full Text] [Related]  

  • 11. Point of care platelet activity measurement in primary PCI [PINPOINT-PPCI]: a protocol paper.
    Johnson TW; Marsden D; Mumford A; Pike K; Mundell S; Butler M; Strange JW; Bowles R; Rogers C; Baumbach A; Reeves BC
    BMC Cardiovasc Disord; 2014 Apr; 14():44. PubMed ID: 24708700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
    Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
    Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Letter by Grove and Kristensen regarding article, "Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction".
    Grove EL; Kristensen SD
    Circ Cardiovasc Interv; 2013 Apr; 6(2):e28. PubMed ID: 23591427
    [No Abstract]   [Full Text] [Related]  

  • 14. Optimal P2Y12 Inhibitor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Network Meta-Analysis.
    Rafique AM; Nayyar P; Wang TY; Mehran R; Baber U; Berger PB; Tobis J; Currier J; Dave RH; Henry TD
    JACC Cardiovasc Interv; 2016 May; 9(10):1036-46. PubMed ID: 27198684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacotherapeutic considerations for the use of prasugrel and ticagrelor to reduce stent thrombosis in patients with acute coronary syndrome.
    Piccolo R; Di Gioia G; Niglio T; D'Anna C; De Rosa R; Strisciuglio T; Bevilacqua M; Piscione F; Cirillo P; Galasso G
    Angiology; 2014 Feb; 65(2):130-6. PubMed ID: 23221279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ticagrelor and prasugrel: two novel, most-promising antiplatelet agents.
    Tagarakis GI
    Recent Pat Cardiovasc Drug Discov; 2010 Nov; 5(3):208-11. PubMed ID: 20874669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual antiplatelet therapy with prasugrel or ticagrelor versus clopidogrel in interventional cardiology.
    Clemmensen P; Dridi NP; Holmvang L
    Cardiovasc Drugs Ther; 2013 Jun; 27(3):239-45. PubMed ID: 23380983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Which antiplatelet agent for whom? Which patient populations benefit most from novel antiplatelet agents (ticagrelor, prasugrel)?
    Varenhorst C; James S
    Curr Cardiol Rep; 2012 Aug; 14(4):486-92. PubMed ID: 22535473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. "Conversations in cardiology": How do you pick the best antiplatelet drug--clopidogrel, prasugrel, ticagrelor for your PCI patient?
    Kern MJ
    Catheter Cardiovasc Interv; 2012 Feb; 79(2):255-62. PubMed ID: 22271555
    [No Abstract]   [Full Text] [Related]  

  • 20. Differential effect of ticagrelor versus prasugrel on coronary blood flow velocity in patients with non-ST-elevation acute coronary syndrome undergoing percutaneous coronary intervention: an exploratory study.
    Alexopoulos D; Moulias A; Koutsogiannis N; Xanthopoulou I; Kakkavas A; Mavronasiou E; Davlouros P; Hahalis G
    Circ Cardiovasc Interv; 2013 Jun; 6(3):277-83. PubMed ID: 23735473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.